Multiplexed biological analyzer planar array apparatus and methods

Information

  • Patent Grant
  • 7910356
  • Patent Number
    7,910,356
  • Date Filed
    Wednesday, February 1, 2006
    18 years ago
  • Date Issued
    Tuesday, March 22, 2011
    13 years ago
Abstract
A planar array having plurality of biological recognition molecules including at least two types of biological recognition molecules distributed about a substrate is disclosed. A first type of biological recognition molecules is distributed according to a first frequency and a second type of biological recognition molecules is distributed according to a second frequency. Another planar array having a plurality of biological recognition molecules including at least two kinds of biological recognition molecules is disclosed. The recognition molecules are distributed about a substrate with first kind of biological recognition molecules distributed at a first height or depth relative to a surface of the substrate and a second kind of biological recognition molecules distributed at a second height or depth relative to the surface. An apparatus including a surface normal interferometry platform including a scanning pathway and a plurality of analyzer molecules adapted to detect the presence or absence of a plurality of target analytes is also disclosed. The plurality of analyzer molecules are distributed about the scanning pathway according to a multiplexing scheme. A method including multiplexing a plurality of kinds of capture molecules about a detection pathway is further disclosed. The method also includes contacting a biological sample to the array, detecting the presence or absence of binding of the plurality of kinds of capture molecules and a plurality of target analytes using interferometry.
Description
TECHNICAL FIELD

The present invention generally relates to a device for detecting the presence of specific biological material in a sample, and more particularly to a laser compact disc system for detecting the presence of biological pathogens and/or analyte molecules bound to target receptors on the disc by sensing changes in the optical characteristics of a probe beam reflected from the disc caused by the pathogens and/or analytes.


BACKGROUND

In many chemical, biological, medical, and diagnostic applications, it is desirable to detect the presence of specific molecular structures in a sample. Many molecular structures such as cells, viruses, bacteria, toxins, peptides, DNA fragments, and antibodies are recognized by particular receptors. Biochemical technologies including gene chips, immunological chips, and DNA arrays for detecting gene expression patterns in cancer cells, exploit the interaction between these molecular structures and the receptors. [For examples see the descriptions in the following articles: Sanders, G. H. W. and A. Manz, Chip-based microsystems for genomic and proteomic analysis. Trends in Anal. Chem., 2000, Vol. 19(6), p. 364-378. Wang, J., From DNA biosensors to gene chips. Nucl. Acids Res., 2000, Vol. 28(16), p. 3011-3016; Hagman, M., Doing immunology on a chip. Science, 2000, Vol. 290, p. 82-83; Marx, J., DNA Arrays reveal cancer in its many forms. Science, 2000, Vol. 289, p. 1670-1672]. These technologies generally employ a stationary chip prepared to include the desired receptors (those which interact with the target analyte or molecular structure under test). Since the receptor areas can be quite small, chips may be produced which test for a plurality of analytes. Ideally, many thousand binding receptors are provided to provide a complete assay. When the receptors are exposed to a biological sample, only a few may bind a specific protein or pathogen. Ideally, these receptor sites are identified in as short a time as possible.


One such technology for screening for a plurality of molecular structures is the so-called immunological compact disk, which simply includes an antibody microarray. [For examples see the descriptions in the following articles: Ekins, R., F. Chu, and E. Biggart, Development of microspot multi-analyte ratiometric immunoassay using dual flourescent-labelled antibodies. Anal. Chim. Acta, 1989, Vol. 227, p. 73-96; Ekins, R. and F. W. Chu, Multianalyte microspot immunoassay—Microanalytical “compact Disk” of the future. Clin. Chem., 1991, Vol. 37(11), p. 1955-1967; Ekins, R., Ligand assays: from electrophoresis to miniaturized microarrays. Clin. Chem., 1998, Vol. 44(9), p. 2015-2030]. Conventional fluorescence detection is employed to sense the presence in the microarray of the molecular structures under test. Other approaches to immunological assays employ traditional Mach-Zender interferometers that include waveguides and grating couplers. [For examples see the descriptions in the following articles: Gao, H., et al., Immunosensing with photo-immobilized immunoreagents on planar optical wave guides. Biosensors and Bioelectronics, 1995, Vol. 10, p. 317-328; Maisenholder, B., et al., A GaAs/AlGaAs-based refractometer platform for integrated optical sensing applications. Sensors and Actuators B, 1997, Vol. 38-39, p. 324-329; Kunz, R. E., Miniature integrated optical modules for chemical and biochemical sensing. Sensors and Actuators B, 1997, Vol. 38-39, p. 13-28; Dübendorfer, J. and R. E. Kunz, Reference pads for miniature integrated optical sensors. Sensors and Actuators B, 1997 Vol. 38-39, p. 116-121; Brecht, A. and G. Gauglitz, recent developments in optical transducers for chemical or biochemical applications. Sensors and Actuators B, 1997, Vol. 38-39, p. 1-7].


While the abovementioned techniques have proven useful for producing and reading assay information within the chemical, biological, medical and diagnostic application industries, developing improved fabrication and reading techniques for planar arrays with significant improvement in performance over existing planar array technology is desirable.


SUMMARY

One embodiment according to the present invention includes a planar array having plurality of biological recognition molecules including at least two types of biological recognition molecules distributed about a substrate. A first type of biological recognition molecules is distributed according to a first frequency and a second type of biological recognition molecules is distributed according to a second frequency.


Another embodiment according to the present invention includes a planar array having plurality of biological recognition molecules including at least two kinds of biological recognition molecules distributed about a substrate. A first kind of biological recognition molecules is distributed at a first height or depth relative to a surface of the substrate and a second kind of biological recognition molecules is distributed at a second height or depth relative to the surface.


A further embodiment according to the present invention includes an apparatus including a surface normal interferometry platform including a scanning pathway and a plurality of analyzer molecules adapted to detect the presence or absence of a plurality of target analytes. The plurality of analyzer molecules are distributed about the scanning pathway according to a multiplexing scheme.


Another embodiment of the present invention includes a method including multiplexing a plurality of kinds of capture molecules about a detection pathway, contacting a biological sample to the array, detecting the presence or absence of binding of the plurality of kinds of capture molecules and a plurality of target analytes using interferometry.


Additional embodiments, aspects, and advantages of the present invention will be apparent from the following description.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a top schematic view of a distribution of elements including multiple analyzer molecules according to one embodiment of the present invention.



FIG. 2 is a graph illustrating harmonic signals indicating the detection of analytes by the analyzer molecules of FIG. 1.



FIG. 3 is a top schematic view of a bio-CD according to one embodiment of the present invention.



FIG. 4 is a side sectional schematic view of a biosensor platform according to one embodiment of the present invention.



FIG. 5 is a side sectional schematic view of a biosensor platform according to one embodiment of the present invention.



FIG. 6 is a top schematic view of a distribution of elements including multiple analyzer molecules according to one embodiment of the present invention.



FIG. 7 is a view of orthogonal bit sequences relating to the distribution of elements of FIG. 6.





DETAILED DESCRIPTION

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated device, and such further applications of the principles of the invention as illustrated therein being contemplated as would normally occur to one skilled in the art to which the invention relates.


With reference to FIG. 1 there is shown a distribution of elements 100 according to one embodiment of the present invention. The distribution of elements 100 includes at least three types of analyzer molecules 110, 120 and 130 distributed about scanning pathway 104 at three frequencies. Analyzer molecules 110 are distributed at a frequency of every other element of distribution 100. Analyzer molecules 120 are distributed at a frequency of every fourth element of distribution 100. Analyzer molecules 130 are distributed at a frequency of every eighth element of distribution 100. Distribution 100 also includes elements 150 which do not include analyzer molecules 110, 120, or 130. Additional types of analyzer molecules could be present at elements 150 and could, for example, be distributed at different frequencies such as every 16 elements, every 32 elements, or at other frequencies. Elements 150 could also not include analyzer molecules. As indicated by ellipses 106 and 108, elements 100 and reading pathway 104 can extend beyond the segment illustrated in FIG. 1 with the distribution of various analyzer molecules occurring at various frequencies as described above.


Scanning footprint 102 travels over the distribution of elements 100 along scanning pathway 104 in the direction indicated by arrow R. In a preferred embodiment of the present invention, the distribution of elements 100 can be about a bio-CD which is scanned with a laser beam to detect the presence or absence of analytes bound to the analyzer molecules. In one embodiment the bio-CD is preferably scanned using surface normal self referencing phase quadrature interferometry techniques. In this embodiment elements 100 might, for example, be microstructures such as radial spokes formed on the surface of the bio-CD, and analyzer molecules 110, 120, and 130 may be immobilized, for example, as monolayers, fractional monolayers, partial monolayers, or near monolayers on surfaces of the microstructures. Furthermore, scanning pathway 104 can be one of multiple substantially concentric tracks which may be scanned with a laser, for example, using interferometry techniques such as phase quadrature interferometric detection techniques. Examples of phase quadrature interferometric techniques include the micro-diffraction quadrature class (“MD-class”) and adaptive optic quadrature class (“AO-class”) as described in U.S. application Ser. No. 10/726,772 filed on Dec. 3, 2003 entitled “Adaptive Interferometric Multi-Analyte High-Speed Biosensor” (published on Aug. 26, 2004 as U.S. Pub. No. 2004/0166593), the contents of which are incorporated herein by reference. Other examples of phase quadrature interferometric techniques include the phase-contrast quadrature class (“PC-class”) as described in U.S. Provisional Patent Application No. 60/649,070, filed Feb. 1, 2005, entitled “Phase-Contrast Quadrature For Spinning Disk Interferometry And Immunological Assay”, U.S. Provisional Patent Application No. 60/755,177, filed Dec. 30, 2005, entitled “Phase-Contrast BioCD: High-Speed Immunoassays at Sub-Picogram Detection Levels”, and U.S. application Ser. No. 11/345,462 being filed the same day as the present application that claims priority to these two provisional applications and entitled “Method And Apparatus For Phase Contrast Quadrature Interferometric Detection Of An Immunoassay”. The disclosures of the utility application entitled “Method And Apparatus For Phase Contrast Quadrature Interferometric Detection Of An Immunoassay” is incorporated herein by reference. In these embodiments, the scanning pathway is preferably a ring shaped track of a bio-CD. During scanning the bio-CD is rotated at a scanning rate, for example, 223 revolutions per minute, to successively pass elements through the footprint of the laser beam. Under these conditions, the spatial frequency of the distribution of elements 100 corresponds to a temporal frequency.


Distribution of elements 100 is one exemplary embodiment of frequency-domain multiplexing in which different analyzer molecules are distributed at different spatial frequencies. Frequency-domain multiplexing can be used to test for many different analytes along a scanning pathway without requiring spatial separation of analyzer molecules used to detect particular analytes into sectors. In embodiments utilizing a rotating disk as a detection platform, systematics that depend on theta, the angular position about the disk, are substantially averaged out using this technique.


In addition to the embodiments described above, a variety of additional exemplary embodiments are also contemplated. For example, elements and analytes might be distributed in a variety of shapes such as substantially circular, oval, ellipsoid, square, polygonal, or other shapes. A variety of scanning pathway configurations might be utilized, including substantially linear or circular pathways, open pathways, closed pathways, curvilinear pathways, or spiral pathways, for example. A variety of frequency distributions of analyzer molecules can be used in addition to or instead of those described above. A variety of spacing of elements or analyzer molecules may also be used, for example, successive elements or analyzer molecules may be adjacent or adjoining, or may be spaced at intervals differing from those shown in connection with FIG. 1, or may overlap or occupy the same position. A variety of substrates and platforms may also be used including disks or chips supporting planar arrays including, for example, those described herein. Additionally, the variations and additional embodiments described elsewhere herein may apply to the present embodiment.


With reference to FIG. 2 there is shown graph 200 illustrating an example of detection of target analytes using the distribution of elements 100 illustrated and described in connection with FIG. 1. The x axis of graph 200 is frequency which increases from origin 206 in the direction indicated by x axis arrow 204. The y axis of graph 200 is harmonic signal intensity which increases from origin 206 in the direction indicated by y axis arrow 202.


As shown in FIG. 2, the results of a scanning of the distribution of elements 100 can be represented in the frequency domain. Harmonic signals 210, 220 and 230 indicate detection of binding of target analytes to analyzer molecules 110, 120, and 130, respectively. Signal 230 has center frequency 231, signal 220 has center frequency 221, and signal 210 has center frequency 211. Center frequencies 231, 221, and 211 correspond to the spatial frequencies of analyzer molecules 130, 120, and 110, respectively, and the rate of scanning. Since the spatial frequency of analyzer molecules 110 is 16 times that of analyzer molecules 130 and 4 times that of analyzer molecules 120, the harmonic signal 210 has a center frequency 211 sixteen times that of the center frequency 231 of harmonic signal 231 and four times that of center frequency 221 of harmonic signal 220. Detection of signals at a variety of different frequencies corresponding to spatial frequencies of analyzer molecules is possible. Furthermore, time domain detection techniques can be utilized.


With reference to FIG. 3 there is shown a bio-CD 300 according to another embodiment of the present invention. Bio-CD 300 includes sectors 310, 320, 330, 340, 350, 360, 370, 380 and 390. A substantially circular scanning pathway 302 is defined about the read surface of Bio-CD 300 and scanning footprint 304 follows pathway 302 when bio-CD 300 is rotated. Bio-CD 300 may also include multiple other scanning pathways substantially concentric with pathway 302 located inside the outer perimeter 306 of bio-CD 300. Additionally, bio-CD 300 may include an aperture located at its center for receiving a device used to rotate bio-CD 300.


Each of sectors 310, 320, 330, 340, 350, 360, 370, 380 and 390 could include a different type of analyzer molecule to test for a different analyte in a single sample, or could include the same type of analyzer molecule and test different samples for the same analyte. Combinations of these two examples are also possible, for example, the eight sectors shown in FIG. 3 could be used to test two samples for four different analytes, four samples for two different analytes, two samples for one analyte and two samples for three analytes, one sample for one analyte another sample for two analytes and another sample for five analytes, or various other combinations using all or some of the sectors for various other combinations of analyzer molecule(s) and test sample(s).


In a preferred embodiment according to the present invention, a bio-CD including a plurality of tracks as reading pathways provides a platform that can be divided into sectors as described above and used in a surface normal self referencing phase quadrature interferometric detection system. One such embodiment preferably includes 1024 interferometric elements per track and is divided into sixteen sectors for receiving sixteen samples. The total number of assays in this case is sixteen times the number of tracks. At 1000 tracks this allows 16,000 assays. Another such preferred embodiment includes 8192 interferometric elements per track and is divided into 128 sectors for receiving 128 samples. The total number of assays in this case is 128 times the number of tracks. For 1000 tracks, this is 128,000 assays. Thus, very high numbers of assays may be conducted in the time required to scan a bio-CD, which can be as little as about twenty minutes or less.


With reference to FIG. 4 there is shown a multi-layer biosensor platform 400 according to one embodiment of the present invention. Platform may be a disk or chip including, for example, those described herein. Platform 400 includes an upper surface 404 and scanning levels 410, 412, and 414 which are positioned at different distances from surface 404. Scanning levels 410, 412, and 414 include interferometric elements 420A, 420B, and 420C, respectively. For simplicity, only a few interferometric elements are labeled, but additional interferometric elements are present as indicated by ellipses 421A, 421B, and 421C. Analyzer molecules may be provided on scanning surfaces of interferometric elements 420A, 420B, and 420C, and may be exposed to test samples via microfluidic channels internal to platform 400. Confocal microscope optics can be used to direct a laser beam 402 to scan interferometric elements 420A, 420B, and 420C. As shown in FIG. 4 laser beam 402 is scanning elements 420B of level 412. Thus, it is possible to isolate a signal from a specific scanning level of platform 400.


In a preferred embodiment of the present invention platform 400 is a multi-level bio-CD. In this embodiment, the interferometric elements can be transparent or partially transparent elements, placed in a stack at different levels in a fashion similar to that of a high-density DVD. To focus at a different level, the disk is moved to or away from the objective, or else the optical train is moved toward or away from the disk or chip.


The embodiments described above in connection with FIGS. 3 and 4 are examples of space domain multiplexing in which spatially separate segments of a biosensor platform carry different analytes. Additionally, the variations and additional embodiments described elsewhere herein may apply to the present embodiment.


With reference to FIG. 5 there is shown a biosensor platform 500 according to one embodiment of the present invention. Platform 500 includes substrate 504 having upper surface 505. Microstructures 510, 520 and 530 are disposed on surface 505 and have a variety of heights. Microstructures 510, 520 and 530 and are scanned by laser beam 502. Laser beam 502 preferably includes a plurality of wavelengths of laser light represented by arrows LA, LB, and LC. The height of microstructure 510 shown by arrows HA is ⅛ wavelength LA, the height of microstructure 520 shown by arrows HB is ⅛ wavelength LB, and the height of microstructure 530 shown by arrows HC is ⅛ wavelength LC. Thus, microstructures 510, 520, and 530 are individually tuned to produce a phase quadrature condition for the different wavelengths LA, LB, and LC, respectively. As described above, each of microstructures 510, 520, and 530 could include a different analyzer molecule immobilized to its surface for detecting a different analyte. It is also contemplated that additional or fewer microstructure heights and/or light wavelengths could be used.


The embodiments shown and described above in connection with FIG. 5 is one example of wavelength-domain multiplexing which includes having multiple types of microstructures on a single track that are individually tuned to different wavelengths. A variety of additional embodiments and variations are also contemplated. In a preferred embodiment according to the present invention biosensor platform 500 is a bio-CD and the scanning of elements is accomplished by rotating the bio-CD to pass the interferometric microstructures through the footprint of the laser beam. In this embodiment microstructures can be radial spokes formed at different heights. The heights can be selected so that a microstructure is in quadrature for one wavelength, but null for a different wavelength. Furthermore, the distribution of analyzer molecules about the microstructures can be according to frequency-domain multiplexing, space-domain multiplexing or code-domain multiplexing schemes including those described above and below.


In other embodiments according to the present invention different height microstructures are not required, rather a laser probe contains a continuum of wavelengths, and readout in the far field can use an imaging spectrometer to separate theta and wavelength, for example, or readout can use interferometry techniques. In one preferred embodiment according to the present invention a phase contrast bio-CD provides an interferometry platform including a multiplexed distribution of analyzer molecules without different height microstructures. This phase contrast platform can be scanned with a plurality of wavelengths to define quadrature conditions and quadrature angles. Different wavelengths interact differently with this phase contrast platform and can be separated during detection to extract independent information from the wavelengths, for example, using interferometry. Multiple discrete wavelengths can be utilized or one or more wavelength continuums can be utilized. Other exemplary platforms not including different height microstructures include surface plasmon resonance platforms including a multiplexed distribution of analyzer molecules. Scanning of such platforms with multiple wavelengths can be read out as angular shifts or as frequency shifts.


Wavelength-domain multiplexing techniques allow probing at many different wavelengths, bringing spectroscopic molecular specificity to bear on the laser-scanning interferometry. There can be significant information contained in the spectral absorption of biomolecules. This information can be used in detecting target analytes in a sample. Additionally, the variations and additional embodiments described elsewhere herein may apply to the present embodiment.


With reference to FIG. 6 there is shown a distribution of elements 600 according to another embodiment of the present invention. The distribution of elements 600 includes three types of analyzer molecules 610, 620 and 630 distributed about scanning pathway 604 according to a pseudorandom sequence or a random sequence. As indicated by ellipses 606 and 608, elements 600 and reading pathway 604 can extend beyond the segment illustrated in FIG. 6 with the distribution of various analyzer molecules occurring pseudorandomly or randomly as described above.


Scanning footprint 602 travels over the distribution of elements 600 along scanning pathway 604 in the direction indicated by arrow RR. In a preferred embodiment of the present invention, the distribution of elements 600 can be on a bio-CD which is scanned with a laser beam to detect the presence or absence of analytes bound to the analyzer molecules preferably using surface normal self referencing phase quadrature interferometry techniques. In this embodiment elements 600 may be microstructures such as radial spokes formed on the surface of the bio-CD and analyzer molecules 610, 620, and 630 may be immobilized as monolayers, fractional monolayers, partial monolayers, or near monolayers on surfaces of the microstructures. Alternatively, in this and other embodiments, the elements may be defined regions on a substrate without microstructures. Furthermore, scanning pathway 604 can be one of multiple substantially concentric tracks which may be scanned with a laser, for example, as described above. In this embodiment, the scanning pathway is preferably a substantially ring shaped track of a bio-CD.


Scanning of distribution of elements 600 can yield a multiplexed bit sequence which can be processed using known orthogonal bit sequence, for example with matched gating techniques, to produce bit sequences corresponding to each analyzer molecule. FIG. 7 shows a group of mutually orthogonal bit sequences 702 corresponding to the occurrences of analyzer molecules 610, 620, and 630 shown and described above in connection with FIG. 6. Orthogonal bit sequence 710 corresponds to the occurrences of molecules 610, orthogonal bit sequence 720 corresponds to the occurrences of molecules 620, and orthogonal bit sequence 730 corresponds to the occurrences of molecules 630.


Distribution of elements 600 is one exemplary embodiment of code-division multiplexing in which different analyzer molecules are distributed according to a known pseudorandom or random sequence. A variety of additional exemplary embodiments are also contemplated. For example, greater numbers of analyzer molecules could be used. Additionally, the variations and additional embodiments described above and below may also apply to the present embodiment.


Various embodiments according to the present invention can include a variety of biosensor platforms including those described above. For example, these platforms include bio-CDs such as micro-diffraction bio-CDs, adaptive-optical bio-CDs, phase-contrast bio-CDs, and others. Details relating to these various classes of bio-CDs can be found, for example, in the aforementioned patent applications incorporated herein by reference. These platforms further include bio-chips, immunological chips, gene chips, DNA arrays, platforms used in connection with fluorescence assays and other platforms and substrates supporting planar arrays including analyzer molecules.


Various embodiments according to the present invention can include a variety of analyzer molecules useful in detecting the presence or absence of a variety of target analytes in a solution to be tested. For example, these analyzer molecules can include antibodies or immunoglobulins, antigens, DNA fragments, cDNA fragments, aptameres, peptides, proteins, and other molecules. Various embodiments according to the present invention can include combinations of one or more the foregoing and other types of analyzer molecules known to those of ordinary skill in the art arranged, for example, in a planar array.


Various embodiments according to the present invention can be used in connection with a variety of scanning and detection techniques. For example, such techniques include interferometry, including surface normal interferometry techniques, and preferably phase quadrature interferometry techniques where one detected optical mode differs in phase from another by about π/2 or an odd integer multiple thereof, and/or self referencing interferometry techniques where a reference wave is generated locally with respect to a signal wave so that the reference and signal waves experience common aberrations and path length changes and thus maintain a constant relative phase without the need for active stabilization of different light paths, florescence techniques and platforms, resonance techniques and platforms, and other techniques and platforms.


As used herein terms relating to properties such as geometries, shapes, sizes, physical configurations, speeds, rates, frequencies, periods, amplitudes, include properties that are substantially or about the same or equal to the properties described unless explicitly indicated to the contrary.


While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only preferred embodiments have been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.

Claims
  • 1. A method for determining the presence or absence of biological material in a sample comprising: multiplexing a plurality of kinds of capture molecules about a detection pathway on a planar array, comprising the steps of: distributing a first kind of capture molecule along the detection pathway at a first spatial frequency,interspersing a second kind of capture molecule among the first kind of capture molecule along the detection pathway at a second spatial frequency, andinterspersing a third kind of capture molecule among the first and second kinds of capture molecules along the detection pathway at a third spatial frequency, each of the first, second and third spatial frequency being different from the other of the first, second and third spatial frequencies;contacting a biological sample to the planar array;scanning the planar array along the detection pathway with a scanning beam traveling over the plurality of kinds of capture molecules to produce a reflected beam containing information from the plurality of kinds of capture molecules; anddetecting the presence or absence of binding of the plurality of kinds of capture molecules and a plurality of target analytes using interferometry and by demultiplexing the reflected beam containing information from the plurality of kinds of capture molecules to determine information of a particular capture molecule.
  • 2. The method of claim 1 wherein the detecting further comprises detecting a first binding using a first wavelength of laser light and a second binding using a second wavelength of laser light.
  • 3. The method of claim 1 wherein the detection pathway is defined along a surface of a bio-optical disk.
  • 4. The method of claim 1 further comprising rotating the pathway in connection with the detecting.
  • 5. The method of claim 1 wherein the detecting uses self-referencing phase quadrature interferometry.
  • 6. The method of claim 1 further comprising demultiplexing information of a particular capture molecule and a particular target analyte in connection with the detecting.
  • 7. The method of claim 1 wherein the first kind of capture molecule is adapted to selectively bind a first type of target analyte.
  • 8. The method of claim 1 wherein the plurality of kinds of capture molecules are selected from at least one of binding cells, viruses, bacteria, toxins, peptides, DNA fragments and antibodies.
  • 9. A method for determining the presence or absence of a plurality of target analytes in a biological sample comprising: obtaining a substrate having a surface with a detection pathway with a first type of biological recognition molecule and a second type of biological recognition molecule frequency-domain multiplexed, wavelength domain multiplexed or code-division multiplexed thereabout, the first type of biological recognition molecule being distributed at a first spatial frequency and the second type of biological recognition molecule being interspersed with the first type of biological recognition molecule along the detection pathway and being distributed at a second spatial frequency, the second spatial frequency being different from the first spatial frequency;exposing the surface of the substrate to the biological sample;directing a probe laser beam at the surface of the substrate;scanning the probe laser beam across at least the detection pathway; anddetecting binding of the first type of biological recognition molecule to at least one of the target analytes using a first wavelength of laser light and binding of the second type of biological recognition molecule to at least another one of the target analytes using a second wavelength of laser light.
  • 10. The method of claim 9 wherein the detection pathway is defined along a surface of a bio-optical disk.
  • 11. The method of claim 9 further comprising rotating the detection pathway to detect the binding of the first and second types of biological recognition molecules.
  • 12. The method of claim 9 wherein the detection step includes an interferometric detection process.
  • 13. The method of claim 12 wherein the interferometric detection process includes a self-referencing phase quadrature interferometric process.
  • 14. The method of claim 9 further comprising demultiplexing information of a particular biological recognition molecule and a particular target analyte in connection with the detection step.
  • 15. The method of claim 9 wherein the biological recognition molecules are selected from at least one of binding cells, viruses, bacteria, toxins, peptides, DNA fragments and antibodies.
  • 16. The method of claim 1, wherein the first kind of capture molecules are disposed at a first height relative to the planar array and the second kind of capture molecules are disposed at a second height relative to the planar array, the first height being different from the second height; and wherein the detecting step further comprises: detecting a first binding using a first wavelength of light, the first height being tuned to produce a phase quadrature condition for the first wavelength of light; anddetecting a second binding using a second wavelength of light, the second height being tuned to produce a phase quadrature condition for the second wavelength of light.
  • 17. The method of claim 1, wherein the multiplexing is frequency-domain multiplexing, wavelength domain multiplexing or code-division multiplexing.
  • 18. The method of claim 9, wherein the first type of biological recognition molecule is positioned at a first height relative to the surface of the substrate, and the second type of biological recognition molecule is positioned at a second height relative to the surface of the substrate, the first height being different from the second height.
  • 19. A method for determining the presence or absence of biological material in a sample comprising: multiplexing a plurality of kinds of capture molecules about a detection pathway on a planar array comprising the steps of: distributing a first kind of capture molecule along the detection pathway at a first spatial frequency,interspersing a second kind of capture molecule among the first kind of capture molecule along the detection pathway at a second spatial frequency, andinterspersing a third kind of capture molecule among the first and second kinds of capture molecules along the detection pathway at a third spatial frequency, each of the first, second and third spatial frequency being different from the other of the first, second and third spatial frequencies;contacting a biological sample to the planar array;scanning the planar array along the detection pathway with a scanning beam traveling over the plurality of kinds of capture molecules to produce a reflected beam containing information from the plurality of kinds of capture molecules; anddetecting the presence or absence of binding of the plurality of kinds of capture molecules and a plurality of target analytes using interferometry and by demultiplexing the reflected beam containing information from the plurality of kinds of capture molecules to determine information of a particular capture molecule, wherein the demultiplexing the reflected beam comprises using the first, second and third spatial frequencies to detect the presence or absence of binding of the first, second and third kinds of capture molecules, respectively, with the plurality of target analytes.
CROSS REFERENCE

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/649,043, entitled “MULTI-PLEXED LASER SCANNING INTERFEROMETRIC BIOCHIPS AND BIODISKS,” filed on Feb. 1, 2005 and the same is expressly incorporated herein by reference.

US Referenced Citations (230)
Number Name Date Kind
3796495 Laub Mar 1974 A
4537861 Elings et al. Aug 1985 A
4649529 Avicola Mar 1987 A
4741620 Wickramasinghe May 1988 A
4876208 Gustafson et al. Oct 1989 A
4899195 Gotoh Feb 1990 A
4975237 Brown Dec 1990 A
RE33581 Nicoli et al. Apr 1991 E
5122284 Braynin et al. Jun 1992 A
5155549 Dhadwal Oct 1992 A
5413939 Gustafson et al. May 1995 A
5478527 Gustafson et al. Dec 1995 A
5478750 Bernstein et al. Dec 1995 A
5491550 Dabbs Feb 1996 A
5494829 Sandstrom et al. Feb 1996 A
5497007 Uritsky et al. Mar 1996 A
5545531 Rava et al. Aug 1996 A
5578499 Ismail Nov 1996 A
5581345 Oki et al. Dec 1996 A
5602377 Beller et al. Feb 1997 A
5621532 Ooki et al. Apr 1997 A
5629044 Rubenchik May 1997 A
5631171 Sandstrom et al. May 1997 A
5653939 Hollis et al. Aug 1997 A
5700046 Van Doren et al. Dec 1997 A
5717778 Chu et al. Feb 1998 A
5736257 Conrad et al. Apr 1998 A
5781649 Brezoczky Jul 1998 A
5786226 Bocker et al. Jul 1998 A
5837475 Dorsel et al. Nov 1998 A
5843767 Beattie Dec 1998 A
5844871 Maezawa Dec 1998 A
5874219 Rava et al. Feb 1999 A
5875029 Jann et al. Feb 1999 A
5883717 DiMarzio et al. Mar 1999 A
5892577 Gordon Apr 1999 A
5900935 Klein et al. May 1999 A
5922617 Wang et al. Jul 1999 A
5935785 Reber et al. Aug 1999 A
5945344 Hayes et al. Aug 1999 A
5955377 Maul et al. Sep 1999 A
5968728 Perttunen et al. Oct 1999 A
5999262 Dobschal et al. Dec 1999 A
6008892 Kain et al. Dec 1999 A
6030581 Virtanen Feb 2000 A
6048692 Maracas et al. Apr 2000 A
6060237 Nygren et al. May 2000 A
6071748 Modlin et al. Jun 2000 A
6099803 Ackley Aug 2000 A
6110748 Reber et al. Aug 2000 A
6121048 Zaffaroni et al. Sep 2000 A
6140044 Besemer et al. Oct 2000 A
6143247 Sheppard, Jr. et al. Nov 2000 A
6177990 Kain et al. Jan 2001 B1
6221579 Everhart et al. Apr 2001 B1
6238869 Kris et al. May 2001 B1
6248539 Ghadiri et al. Jun 2001 B1
6249593 Chu et al. Jun 2001 B1
6256088 Gordon Jul 2001 B1
6271924 Ngoi et al. Aug 2001 B1
6287783 Maynard et al. Sep 2001 B1
6287850 Besemer et al. Sep 2001 B1
6312901 Virtanen Nov 2001 B2
6312961 Voirin et al. Nov 2001 B1
6319468 Sheppard, Jr. et al. Nov 2001 B1
6319469 Mian et al. Nov 2001 B1
6320665 Ngoi et al. Nov 2001 B1
6327031 Gordon Dec 2001 B1
6339473 Gordon Jan 2002 B1
6342349 Virtanen Jan 2002 B1
6342395 Hammock et al. Jan 2002 B1
6345115 Ramm et al. Feb 2002 B1
6350413 Reichert et al. Feb 2002 B1
6355429 Nygren et al. Mar 2002 B1
6368795 Hefti Apr 2002 B1
6376258 Hefti Apr 2002 B2
6381025 Bornhop et al. Apr 2002 B1
6387331 Hunter May 2002 B1
6395558 Duveneck et al. May 2002 B1
6395562 Hammock et al. May 2002 B1
6399365 Besemer et al. Jun 2002 B2
6403957 Fodor et al. Jun 2002 B1
6416642 Alajoki et al. Jul 2002 B1
6469787 Meyer et al. Oct 2002 B1
6476907 Gordon Nov 2002 B1
6483585 Yang Nov 2002 B1
6483588 Graefe et al. Nov 2002 B1
6496267 Takaoka Dec 2002 B1
6496309 Bliton et al. Dec 2002 B1
6504618 Morath et al. Jan 2003 B2
6518056 Schembri et al. Feb 2003 B2
6551817 Besemer et al. Apr 2003 B2
6566069 Virtanen May 2003 B2
6584217 Lawless et al. Jun 2003 B1
6591196 Yakhini et al. Jul 2003 B1
6596483 Choong et al. Jul 2003 B1
6602702 McDevitt et al. Aug 2003 B1
6623696 Kim et al. Sep 2003 B1
6624896 Neal et al. Sep 2003 B1
6649403 McDevitt et al. Nov 2003 B1
6653152 Challener Nov 2003 B2
6656428 Clark et al. Dec 2003 B1
6685885 Nolte et al. Feb 2004 B2
6687008 Peale et al. Feb 2004 B1
6709869 Mian et al. Mar 2004 B2
6720177 Ghadiri et al. Apr 2004 B2
6733977 Besemer et al. May 2004 B2
6734000 Bhatia May 2004 B2
6737238 Suzuki et al. May 2004 B2
6743633 Hunter Jun 2004 B1
6760298 Worthington et al. Jul 2004 B2
6766817 da Silva Jul 2004 B2
6770447 Maynard et al. Aug 2004 B2
6783938 Nygren et al. Aug 2004 B2
6787110 Tiefenthaler Sep 2004 B2
6791677 Kawai et al. Sep 2004 B2
6803999 Gordon Oct 2004 B1
6806963 Walti et al. Oct 2004 B1
6819432 Pepper et al. Nov 2004 B2
6836338 Opsal et al. Dec 2004 B2
6844965 Engelhardt Jan 2005 B1
6847452 Hill Jan 2005 B2
6878555 Anderson et al. Apr 2005 B2
6891791 Gutin May 2005 B1
6897965 Ghadiri et al. May 2005 B2
6917421 Wihl et al. Jul 2005 B1
6917432 Hill et al. Jul 2005 B2
6918404 da Silva Jul 2005 B2
6937323 Worthington et al. Aug 2005 B2
6955878 Kambara et al. Oct 2005 B2
6958131 Tienfenthaler Oct 2005 B2
6980299 de Boer Dec 2005 B1
6980677 Niles et al. Dec 2005 B2
6987569 Hill Jan 2006 B2
6990221 Shams Jan 2006 B2
6992769 Gordon Jan 2006 B2
6995845 Worthington Feb 2006 B2
7008794 Goh et al. Mar 2006 B2
7012249 Krutchinsky et al. Mar 2006 B2
7014815 Worthington et al. Mar 2006 B1
7026131 Hurt et al. Apr 2006 B2
7027163 Angeley Apr 2006 B2
7031508 Lawless et al. Apr 2006 B2
7033747 Gordon Apr 2006 B2
7061594 Worthington et al. Jun 2006 B2
7070987 Cunningham et al. Jul 2006 B2
7077996 Randall et al. Jul 2006 B2
7083920 Werner et al. Aug 2006 B2
7087203 Gordon et al. Aug 2006 B2
7088650 Worthington et al. Aug 2006 B1
7091034 Virtanen Aug 2006 B2
7091049 Boga et al. Aug 2006 B2
7094609 Demers Aug 2006 B2
7098041 Kaylor et al. Aug 2006 B2
7102752 Kaylor et al. Sep 2006 B2
7106513 Moon et al. Sep 2006 B2
7110094 Gordon Sep 2006 B2
7110345 Worthington et al. Sep 2006 B2
7118855 Cohen et al. Oct 2006 B2
7141378 Miller et al. Nov 2006 B2
7141416 Krutzik Nov 2006 B2
7145645 Blumenfeld et al. Dec 2006 B2
7148970 de Boer Dec 2006 B2
7200088 Worthington et al. Apr 2007 B2
7221632 Worthington May 2007 B2
20010055812 Mian et al. Dec 2001 A1
20020001546 Hunter et al. Jan 2002 A1
20020008871 Poustka et al. Jan 2002 A1
20020045276 Yguerabide et al. Apr 2002 A1
20020051973 Delenstarr et al. May 2002 A1
20020058242 Demers May 2002 A1
20020085202 Gordon Jul 2002 A1
20020097658 Worthington et al. Jul 2002 A1
20020106661 Virtanen Aug 2002 A1
20020127565 Cunningham et al. Sep 2002 A1
20020135754 Gordon Sep 2002 A1
20020151043 Gordon Oct 2002 A1
20020192664 Nygren et al. Dec 2002 A1
20030026735 Nolte et al. Feb 2003 A1
20030035352 Worthington Feb 2003 A1
20030054376 Mullis et al. Mar 2003 A1
20030112446 Miller et al. Jun 2003 A1
20030133640 Tiefenthaler Jul 2003 A1
20030134330 Ravkin et al. Jul 2003 A1
20040002085 Schembri et al. Jan 2004 A1
20040058455 Grier et al. Mar 2004 A1
20040078337 King et al. Apr 2004 A1
20040106130 Besemer et al. Jun 2004 A1
20040132172 Cunningham et al. Jul 2004 A1
20040150829 Koch et al. Aug 2004 A1
20040155309 Sorin et al. Aug 2004 A1
20040166525 Besemer et al. Aug 2004 A1
20040166593 Nolte et al. Aug 2004 A1
20040223881 Cunningham et al. Nov 2004 A1
20040229254 Clair Nov 2004 A1
20040247486 Tiefenthaler Dec 2004 A1
20040258927 Conzone et al. Dec 2004 A1
20050002827 McIntyre et al. Jan 2005 A1
20050003459 Krutzik Jan 2005 A1
20050019901 Matveeva et al. Jan 2005 A1
20050042628 Rava et al. Feb 2005 A1
20050084422 Kido et al. Apr 2005 A1
20050084895 Besemer et al. Apr 2005 A1
20050106746 Shinn et al. May 2005 A1
20050123907 Rava et al. Jun 2005 A1
20050131745 Keller et al. Jun 2005 A1
20050158819 Besemer et al. Jul 2005 A1
20050176058 Zaffaroni et al. Aug 2005 A1
20050191630 Besemer et al. Sep 2005 A1
20050214950 Roeder et al. Sep 2005 A1
20050226769 Shiga Oct 2005 A1
20050248754 Wang et al. Nov 2005 A1
20050254062 Tan et al. Nov 2005 A1
20050259260 Wakita Nov 2005 A1
20050272037 Garey et al. Dec 2005 A1
20060040380 Besemer et al. Feb 2006 A1
20060078935 Werner et al. Apr 2006 A1
20060204399 Freeman et al. Sep 2006 A1
20060210449 Zoval et al. Sep 2006 A1
20060223172 Bedingham et al. Oct 2006 A1
20060234267 Besemer et al. Oct 2006 A1
20060256676 Nolte et al. Nov 2006 A1
20060257939 Demers Nov 2006 A1
20060269450 Kim et al. Nov 2006 A1
20060270064 Gordon et al. Nov 2006 A1
20070003436 Nolte et al. Jan 2007 A1
20070003979 Worthington Jan 2007 A1
20070070848 Worthington et al. Mar 2007 A1
20070077599 Krutzik Apr 2007 A1
20070077605 Hurt et al. Apr 2007 A1
Foreign Referenced Citations (13)
Number Date Country
1189062 Mar 2002 EP
1424549 Jun 2004 EP
WO 9104489 Apr 1991 WO
WO 9104491 Apr 1991 WO
WO 9113353 Sep 1991 WO
WO 9214136 Aug 1992 WO
WO 9403774 Feb 1994 WO
WO 9837238 Aug 1998 WO
WO 0000265 Jan 2000 WO
WO 0039584 Jul 2000 WO
WO 0111310 Feb 2001 WO
WO 0144441 Jun 2001 WO
WO 2006075797 Jul 2006 WO
Related Publications (1)
Number Date Country
20070003925 A1 Jan 2007 US
Provisional Applications (1)
Number Date Country
60649043 Feb 2005 US